2007.06.12 - GAP OPEN - IDIX

Pre-market:

IDIX - +12% gap a pre-marketben....

Idenix Pharma Says Valopicitabine Achieved Both Primary, Secondary Endpoints In Phase II Study Of Hepatitis C Patients

"(RTTNews) - Idenix Pharmaceuticals, Inc. (IDIX) announced results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine, Idenix's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin, the current standard of care, in patients infected with the genotype-1 strain of the hepatitis C virus.

This study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin.

Valopicitabine achieved both primary and secondary endpoints of study and no negative drug-drug interaction was observed between valopicitabine and ribavirin."

Market open:

Az IDIX ide-oda kóvályog...

Az IDIX leroskadt, a többi meg smafu....

A HOFF kitörőben...

Nem igazán ment feljebb....

Market closed